Prodrugs pp 507-524 | Cite as

Monoclonal Antibody Drug Conjugates for Cancer Therapy

  • Peter D. Senter
  • Damon L. Meyer
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


A great deal of interest has surrounded the use of monoclonal antibodies (mAbs) and mAb-based regimens for cancer therapy (Dubowchik and Walker, 1999; Carter, 2001; Meyer and Senter, 2003; Trail et al., 2003; Guillemard and Saragovi, 2004). The rationale for such work is conceptually appealing since mAbs are known to exhibit higher specificity profiles than conventional anticancer drugs and should, therefore, be safely administered and potentially quite effective. Indeed, several mAbs and mAb-based reagents are now clinically approved, including Rituxan (rituximab) for non-Hodgkin’s lymphoma (King and Younes, 2001), Panorex (edrecolomab) for colorectal carcinoma (Schwartzberg, 2001), Herceptin (trastuzamab) for metastatic breast cancer (Yarden and Sliwkowski, 2001), and Avastin for colorectal carcinoma (Ferrara et al., 2004). The only clinically approved mAb-drug conjugate is Mylotarg (gemtuzumab ozogamicin). Bexxar (tositumomab), and Zevalin (ibritumomab) are clinically approved mAb-radioisotope conjugates used for the treatment of lymphomas (Hernandez and Knox, 2004). Many other mAbs and mAb-conjugates are in advanced clinical trials (Carter, 2001; Schultes and Nicodemus, 2004).


Acute Myeloid Leukemia Drug Release Maximum Tolerate Dose Acute Myeloid Leukemia Patient Anaplastic Large Cell Lymphoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Apelgren LD, Zimmerman DL, Briggs SL, and Bumol TF. Antitumor Activity of the Monoclonal Antibody-Vinca Alkaloid Immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a Nude Mouse Model of Human Ovarian Cancer. Cancer Res 1990; 50:3540–3544PubMedGoogle Scholar
  2. Apelgren LD, Bailey DL, Briggs SL, Barton RL, Guttman-Carlisle D, Koppel GA, Nichols CL, Scott WL, Lindstrom TD, Baker AL and Bumol TF. Chemoimmunoconjugate Development for Ovarian Carcinoma Therapy: Preclinical Studies with Vinca Alkaloid-monoclonal Antibody Constructs. Bioconjug Chem 1993; 4:121–126PubMedCrossRefGoogle Scholar
  3. Appelbaum FR, Brown PA, Sandmaier BM, Storb R, Fisher DR, Shulman HM, Graham TC, Schuening FG, Deeg HJ, and Bianco JA. Specific Marrow Ablation Before Marrow Transplantation Using an Aminophosphonic Acid Conjugate 166Ho-EDTMP. Blood 1992; 80: 1608–1613PubMedGoogle Scholar
  4. Boghaert ER, Sridharan L, Armellino DC, Khandke KM, DiJoseph JF, Kunz A, Dougher MM, Jiang F, Kalyandrug LB, Hamann PR, Frost P, Damle NK. Antibody-targeted Chemotherapy with the Calicheamicin Conjugate hu3S193-N-acetyl gamma Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-positive Human Carcinoma Cells and Xenografts. Clin Cancer Res 2004;10:4538–4549.PubMedCrossRefGoogle Scholar
  5. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, and Pazdur R. Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia. Clin Cancer Res 2001; 7: 1490–1496PubMedGoogle Scholar
  6. Carter P. Improving the Efficacy of Antibody-based Cancer Therapies. Nat Rev Cancer 2001; 1:118–129PubMedCrossRefGoogle Scholar
  7. Chari RV, Jackel KA, Bourret LA, Derr SM, Tadayoni BM, Mattocks KM, Shah SA, Liu C, Blattler WA, and Goldmacher VS. Enhancement of the Selectivity and Antitumor Efficacy of a CC-1065 Analogue Through Immunoconjugate Formation. Cancer Res 1995; 55:4079–4084PubMedGoogle Scholar
  8. Damle NK and Frost P. Antibody-targeted Chemotherapy with Immunoconjugates of Calicheamicin. Curr Opin Pharmacol 2003; 3:386–390PubMedCrossRefGoogle Scholar
  9. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, and Damle NK. Antibody-targeted Chemotherapy With CMC-544: A CD22-targeted Immunoconjugate of Calicheamicin for the Treatment of B-lymphoid Malignancies. Blood 2004; 103:1807–1814PubMedCrossRefGoogle Scholar
  10. DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann PR, Zinkewich-Peotti K, Stephens S, Weir N, and Damle NK. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother 2004; in pressGoogle Scholar
  11. Doronina SO, Toki BE, Torgov M, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, and Senter PD Development of Potent and Highly Efficacious Monoclonal Antibody Auristatin Conjugates for Cancer Therapy. Nat Biotechnol 2003; 21:778–784PubMedCrossRefGoogle Scholar
  12. Dubowchik GM and Firestone RA. Cathepsin B-sensitive Dipeptide Prodrugs. 1. A Model Study of Structural Requirements for Efficient Release of Doxorubicin. Bioorg Med Chem Lett 1998; 8:3341–3346PubMedCrossRefGoogle Scholar
  13. Dubowchik GM and Walker MA. Receptor-mediated and Enzyme-dependent Targeting of Cytotoxic Anticancer Drugs. Pharmacol Ther 1999; 83:67–123PubMedCrossRefGoogle Scholar
  14. Dubowchik GM, Mosure K, Knipe JO, and Firestone RA. Cathepsin B-sensitive Dipeptide Prodrugs. 2. Models of Anticancer Drugs Paclitaxel (Taxol), Mitomycin C and Doxorubicin. Bioorg Med Chem Lett 1998; 8:3347–3352PubMedCrossRefGoogle Scholar
  15. Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, and Trail PA. Cathepsin B-labile Dipeptide Linkers for Lysosomal Release of Doxorubicin From Internalizing Immunoconjugates: Model Studies of Enzymatic Drug Release and Antigen-specific In Vitro Anticancer Activity. Bioconjug Chem 2002a; 13:855–869PubMedCrossRefGoogle Scholar
  16. Dubowchik GM, Radia S, Mastalerz H, Walker MA, Firestone RA, Dalton King H, Hofstead SJ, Willner D, Lasch SJ, and Trail PA. Doxorubicin Immunoconjugates Containing Bivalent, Lysosomally-cleavable Dipeptide Linkages. Bioorg Med Chem Lett 2002b; 12:1529–1532PubMedCrossRefGoogle Scholar
  17. Ferrara N, Hillan KJ, Gerber HP, and Novotny W. Discovery and Development of Bevacizumab, and Anti-VEGF Antibody for Treating Cancer. Nat Rev Drug Disc 2004; 3:391–400CrossRefGoogle Scholar
  18. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, and Wahl AF. cAC10-vcMMAE, an Anti-CD30-monomethyl Auristatin E Conjugate With Potent and Selective Antitumor Activity. Blood 2003; 102:1458–1465PubMedCrossRefGoogle Scholar
  19. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, and Estey EH. Mylotarg (Gemtuzumab Ozogamicin) Therapy is Associated with Hepatic Venoocclusive Disease in Patients Who Have Not Received Stem Cell Transplantation. Cancer 2001; 92:406–413PubMedCrossRefGoogle Scholar
  20. Gillespie AM, Broadhead TJ, Chan SY, Owen J, Farnsworth AP, Sopwith M, and Coleman RE. Phase I Open Study of the Effects of Ascending Doses of the Cytotoxic Immunoconjugate CMB-401 (hCTMO1-calicheamicin) in Patients with Epithelial Ovarian Cancer. Ann Oncol 2000; 11:735–741PubMedCrossRefGoogle Scholar
  21. Guillemard V and Saragovi HU. Novel Approaches for Targeted Cancer Therapy. Curr Cancer Drug Targets 2004; 4: 313–326PubMedCrossRefGoogle Scholar
  22. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, Mountain A, Flowers DA, and Bernstein I. Gemtuzumab Ozogamicin, a Potent and Selective anti-CD33 Antibodycalicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Bioconjug Chem 2002a; 13:47–58PubMedCrossRefGoogle Scholar
  23. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, and Bernstein I. An Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of Linker. Bioconjug Chem 2002b; 13:40–46PubMedCrossRefGoogle Scholar
  24. Hernandez MC and Knox SJ. Radiobiology of Radioimmunotherapy: Targeting CD20 B-cell antigen in Non-Kodgkin’s Lymphoma. Int J Radiat Oncol Biol Phys 2004; 59:1269–1271Google Scholar
  25. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, and Upeslacis J. Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibiotics. Cancer Res 1993; 53:3336–3342PubMedGoogle Scholar
  26. Jain RK. Physiological Barriers to Delivery of Monoclonal Antibodies and Other Macromolecules in Tumors Cancer Res 1990; 50: 814–819Google Scholar
  27. Kaneko T, Willner D, Monkovic I, Knipe JO, Braslawsky GR, Greenfield RS, and Vyas DM. New Hydrazone Derivatives of Adriamycin and Their Immunoconjugates—A Correlation Between Acid Stability and Cytotoxicity. Bioconjug Chem 1991; 2:133–141PubMedCrossRefGoogle Scholar
  28. King KM and Younes A. Rituximab: Review and Clinical Applications Focusing on Non-Hodgkin’s Lymphoma. Exert Rev Anticancer Ther 2001; 1:177–186CrossRefGoogle Scholar
  29. King HD, Dubowchik GM, Mastalerz H, Willner D, Hofstead SJ, Firestone RA, Lasch SJ, and Trail PA. Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains. J Med Chem 2002; 45:4336–4343PubMedCrossRefGoogle Scholar
  30. Laguzza BC, Nichols CL, Briggs SL, Cullinan GJ, Johnson DA, Starling JJ, Baker AL, Bumol TF, Corvalan JR. New Antitumor Monoclonal Antibody-Vinca Conjugates LY203725 and Related Compounds: Design, Preparation, and Representative In Vivo Activity. J Med Chem 1989; 32:548–555PubMedCrossRefGoogle Scholar
  31. Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, Blattler WA, and Chari RV. Eradication of Large Colon Tumor Xenografts by Targeted Delivery of Maytansinoids. Proc Natl Acad Sci USA 1996; 93:8618–8623PubMedCrossRefGoogle Scholar
  32. Meredith R, Shen S, Macey D, Khazaeli MB, Carey D, Robert F, and LoBuglio A. Comparison of Biodistribution, Dosimetry, and Outcome From Clinical Trials of Radionuclide-CC49 Antibody Therapy. Cancer Biother Radiopharm 2003; 18:393–404PubMedCrossRefGoogle Scholar
  33. Meyer DL and Senter PD. Recent Advances in Antibody Drug Conjugates for Cancer Therapy. Ann Rep Med Chem 2003; 38:229–237CrossRefGoogle Scholar
  34. Miller ML, Roller, EE, Zhao RY, Leece BA, Ab O, Baloglu E, Goldmacher VS, and Chari RVJ. Synthesis of Taxoids with Improved Cytotoxicity and Solubility for Use in Tumor-Specific Delivery. J Med Chem 2004; 47:4802–4805PubMedCrossRefGoogle Scholar
  35. Mosure KW, Henderson AJ, Klunk LJ, Knipe JO. Disposition of Conjugate-bound and Free Doxorubicin in Tumor-bearing Mice Following Administration of a BR96-doxorubicin Immunoconjugate (BMS 182248). Cancer Chemother Pharmacol 1997; 40:251–258PubMedCrossRefGoogle Scholar
  36. Ojima I, Geng X, Wu X, Qu C, Borella CP, Xie H, Wilhelm SD, Leece BA, Bartle LM, Goldmacher VS, and Chari RV. Tumor-specific Novel Taxoid-monoclonal Antibody Conjugates. J Med Chem 2002; 45:5620–5623PubMedCrossRefGoogle Scholar
  37. Otani M, Natsume T, Watanabe JI, Kobayashi M, Murakoshi M, Mikami T, Nakayama T. TZT-1027, An Antimicrotubule Agent, Attacks Tumor Vasculature and Induces Tumor Cell Death. Jpn J Cancer Res 2000; 91:837–844PubMedGoogle Scholar
  38. Patel VF, Hardin JN, Starling JJ, and Mastro JM. Novel Trityl Linked Drug Immunoconjugates for Cancer Therapy. Bioorg Med Chem Lett 1995; 5:507–512CrossRefGoogle Scholar
  39. Payne G. Progress in Immunoconjugate Cancer Therapeutics. Cancer Cell 2003; 3:207–212PubMedCrossRefGoogle Scholar
  40. Roguska MA, Pedersen JT, Henry AH, Searle SM, Roja CM, Avery B, Hoffee M, Cook S, Lambert JM, Blattler WA, Rees AR, and Guild BC. A Comparison of two Murine Monoclonal Antibodies Humanized by CDR-Grafting and Variable Domain Resurfacing. Protein Eng 1996; 9:895–904PubMedCrossRefGoogle Scholar
  41. Saad ED, Kraut EH, Hoff PM, Moore DF, Jones D, Pazdur R, and Abbruzzese JL. Phase II Study of Dolastatin-10 as First-line Treatment for Advanced Colorectal Cancer. Am J Clin Oncol 2002; 25:451–453PubMedCrossRefGoogle Scholar
  42. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, Jones D, Daniel CR, LeBherz D, Brewer H, Onetto N, aqnd LoBuglio AF. Phase I Trial of the Anti-Lewis Y Drug Immunoconjugate BR96-doxorubicin in Patients with Lewis Y-expressing Epithelial Tumors. J Clin Oncol 2000; 11:2282–2292Google Scholar
  43. Schultes BC and Nicodemus CF. Using Antibodies in Tumour Immunotherapy. Expert Opin Biol Ther 2004; 4:1265–1284PubMedCrossRefGoogle Scholar
  44. Schwartzberg LS. Clinical Experience with Edrecolomab: A Monoclonal Antibody Therapy for Colorectal Carcinoma. Crit Rev Oncol Hematol 2001; 40:17–24PubMedCrossRefGoogle Scholar
  45. Shen WC and Ryser HJ. Cis-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Model of pH-Sensitive Linkage Releasing Drug From a Lysosomotropic Conjugate. Biochem Biophys Res Commun 1981; 102:1048–1054PubMedCrossRefGoogle Scholar
  46. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, and Bernstein ID. Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate. Blood 1999; 93:3678–3684PubMedGoogle Scholar
  47. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, and Appelbaum FR. Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with CD33-Positive Acute Myeloid Leukemia in First Relapse. J Clin Oncol 2001; 19:3244–3254PubMedGoogle Scholar
  48. Srinivasachar K and Neville DM. New Protein Cross-linking Reagents That are Cleaved by Mild Acid Biochemistry 1989; 28:2501–2509PubMedCrossRefGoogle Scholar
  49. Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Blakey DC, and Newell DR. Improved Antitumor Effects of Immunotoxins Prepared with Deglycosylated Ricin A-chain and Hindered Disulfide Linkages. Cancer Res 1988; 48:6396–6403PubMedGoogle Scholar
  50. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, and Slichenmyer W. Randomized Phase II Study of BR96-doxorubicin Conjugate in Patients with Metastatic Breast Cancer. J Clin Oncol 1999; 17:478–484PubMedGoogle Scholar
  51. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, and Rowinsky EK. Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. J Clin Oncol 2003; 21:211–222PubMedCrossRefGoogle Scholar
  52. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellstrom I, and Hellstrom KE Cure of Xenografted Human Carcinomas by BR96-doxorubicin Immunoconjugates. Science 1993; 261:212–215PubMedCrossRefGoogle Scholar
  53. Trail PA, Willner D, Bianchi AB, Henderson AJ, TrailSmith MD, Girit E, Lasch S, Hellstrom I, and Hellstrom KE. Enhanced Antitumor Activity of Paclitaxel in Combination with the Anticarcinoma Immunoconjugate BR96-doxorubicin. Clin Cancer Res 1999; 5:3632–3638PubMedGoogle Scholar
  54. Trail PA, King, HD, and Dubowchik GM. Monoclonal Antibody Drug Immunoconjugates for Targeted Treatment of Cancer. Cancer Immunol Immunother 2003; 52:328–337PubMedGoogle Scholar
  55. van der Jagt RH, Badger CC, Appelbaum FR, Press OW, Matthews DC, Eary JF, Krohn KA, and Bernstein ID. Localization of Radiolabeled Antimyeloid Antibodies in a Human Acute Leukemia Xenograft Tumor Model. Cancer Res 1992; 52:89–94PubMedGoogle Scholar
  56. Vitetta ES, Thorpe PE, and Uhr JW. Immunotoxins: Magic Bullets or Misguided Missiles? Trends Pharmacol Sci 1993; 14:148–154PubMedCrossRefGoogle Scholar
  57. Wahl AF, Donaldson KL, Mixan BJ, Trail PA, and Siegall CB. Selective Tumor Sensitization to Taxanes with the mAb-Drug Conjugate cBR96-Doxorubicin. Int J Cancer 2001; 93:590–600PubMedCrossRefGoogle Scholar
  58. Walker MA, Dubowchik GM, Hofstead SJ, Trail PA, and Firestone RA. Synthesis of an Immunoconjugate of Camptothecin. Bioorganic Med Chem Lett 2002; 12:217–219CrossRefGoogle Scholar
  59. Walker MA, King HD, Dalterio RA, Trail, P, Firestone R, and Dubowchik GM, Monoclonal Antibody Mediated Intracellular Targeting of Tallysomycin S(10b). Bioorg Med Chem Lett 2004; 14:4323–4327PubMedCrossRefGoogle Scholar
  60. Yarden Y and Sliwkowski MX. Untangling the ErbB Signalling Network. Nat Rev Mol Cell Biol 2001; 2:127–137PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Peter D. Senter
    • 1
  • Damon L. Meyer
    • 1
  1. 1.Seattle Genetics, Inc.Bothell

Personalised recommendations